Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

Shareholders: roll up to an investor meeting near you

Ahead of the clinical trial results to be released mid-year, Dimerix CEO Kathy Harrison will be running shareholder information sessions in most Australian capital cities. Dates for Perth, Melbourne, Adelaide and Sydney are available here. [...]

ASX announcement – Proactive investor presentation

To read the announcement and the presentation click here

Shareholder newsletter

Did you know Dimerix is at the forefront of developing innovative new medicines for patients with chronic kidney disease? To read our latest newsletter, please click here.

ASX Release – NDF Analyst Report

To see the report please click here

Read More

Media Coverage

NDF Research Analyst Report March 2017

Read the report on their website. 

Corporate presentation November 2016

To view our most recent presentation please click here

NDF Research: Favourable Interim Data with DMX-200

To read report please click here

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates